Last reviewed · How we verify
RJK-RT2831 dose-escalation phase Ia
RJK-RT2831 dose-escalation phase Ia is a Small molecule drug developed by Nanjing RegeneCore Biotech Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | RJK-RT2831 dose-escalation phase Ia |
|---|---|
| Sponsor | Nanjing RegeneCore Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RJK-RT2831 dose-escalation phase Ia CI brief — competitive landscape report
- RJK-RT2831 dose-escalation phase Ia updates RSS · CI watch RSS
- Nanjing RegeneCore Biotech Co., Ltd. portfolio CI
Frequently asked questions about RJK-RT2831 dose-escalation phase Ia
What is RJK-RT2831 dose-escalation phase Ia?
RJK-RT2831 dose-escalation phase Ia is a Small molecule drug developed by Nanjing RegeneCore Biotech Co., Ltd..
Who makes RJK-RT2831 dose-escalation phase Ia?
RJK-RT2831 dose-escalation phase Ia is developed by Nanjing RegeneCore Biotech Co., Ltd. (see full Nanjing RegeneCore Biotech Co., Ltd. pipeline at /company/nanjing-regenecore-biotech-co-ltd).
What development phase is RJK-RT2831 dose-escalation phase Ia in?
RJK-RT2831 dose-escalation phase Ia is in Phase 1.